Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
Medicines, including insulin, to be available in 40 lower-income countries
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Tislelizumab is now approved for seven indications in China
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
Subscribe To Our Newsletter & Stay Updated
